Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC cut its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 12.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,786 shares of the company’s stock after selling 1,195 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Mirum Pharmaceuticals were worth $396,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MIRM. Jones Financial Companies Lllp lifted its stake in Mirum Pharmaceuticals by 100.0% during the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock valued at $30,000 after purchasing an additional 357 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Mirum Pharmaceuticals during the fourth quarter valued at approximately $35,000. GF Fund Management CO. LTD. acquired a new stake in Mirum Pharmaceuticals during the fourth quarter valued at approximately $42,000. AlphaQuest LLC lifted its stake in Mirum Pharmaceuticals by 969.6% during the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company’s stock valued at $76,000 after purchasing an additional 1,658 shares during the last quarter. Finally, Summit Investment Advisors Inc. lifted its stake in Mirum Pharmaceuticals by 8.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company’s stock valued at $172,000 after purchasing an additional 312 shares during the last quarter.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 564 shares of the firm’s stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $48.25, for a total transaction of $27,213.00. Following the transaction, the senior vice president owned 2,903 shares in the company, valued at approximately $140,069.75. This trade represents a 16.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 14.36% of the company’s stock.

Mirum Pharmaceuticals Stock Down 0.8%

MIRM stock opened at $53.01 on Friday. Mirum Pharmaceuticals, Inc. has a 52-week low of $36.17 and a 52-week high of $54.23. The company’s 50 day simple moving average is $47.19 and its 200-day simple moving average is $45.78. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.22 and a quick ratio of 3.04. The firm has a market capitalization of $2.63 billion, a P/E ratio of -32.93 and a beta of 0.97.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.05. The company had revenue of $111.59 million during the quarter, compared to analyst estimates of $98.47 million. Mirum Pharmaceuticals had a negative net margin of 20.39% and a negative return on equity of 33.63%. The company’s revenue for the quarter was up 61.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.54) EPS. As a group, equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Analyst Upgrades and Downgrades

MIRM has been the subject of several recent research reports. JMP Securities increased their target price on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a “market outperform” rating in a research note on Friday, May 9th. Wall Street Zen lowered shares of Mirum Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, July 6th. Raymond James Financial reissued a “strong-buy” rating on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 13th. Finally, HC Wainwright restated a “buy” rating and set a $73.00 price target on shares of Mirum Pharmaceuticals in a report on Monday, May 19th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Mirum Pharmaceuticals presently has an average rating of “Buy” and an average price target of $65.50.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.